 Okay, can I have the last slide please? So we're going to close today by talking a little bit more about the research trials that are the next generation of trials throughout the country, give you some insight, answer your questions, and then send you off to enjoy the rest of your beautiful Saturday. So when we think about kidney cancer, we think about patients at high risk for, high risk after having a resection, whoops what did I do, thank you, newly diagnosed, localized, and we think about the options for people that are in the journey of kidney cancer that we're either having to consider alternatives. So one of the things that I think is the guiding principle for you as a patient is there really is no one time that I think you've heard throughout the day when to ask your doctors about clinical trial opportunities. It can be early, it can be in the middle of treatment, it can be later depending upon how you've done, and my own view is that doctors that dismiss the opportunity to participate in a clinical trial are doctors that may have their best intentions in mind, but you have to be the best advocate for yourselves. And what I mean by that is you may have to get information, use resources, seek out a second opinion, and find out what other options are out there for you, especially as you're making transitions from one treatment to another. One of the things that we're seeing in kidney cancer today different than just three or four years ago is that many of the trials that we do prevent participation if you've had too much prior therapy. So if you've had one, two, three, four, five things, many of the trials that we and others are doing around the world and in the United States only are looking at treatments and people that have had one or two or three prior therapies. So the time point with which to ask and answer those questions for yourself is the time point when a change in treatment is being planned. And generally, when you have a change in treatment being planned, you have the time to reflect to make sure that you're doing the right thing in terms of making that decision. Rarely do you need to make a decision in 24 hours to receive therapy. So some of the things that we have here, which are just examples of what's going on around the country. So what's called the Everest trial is a trial that's in almost 1,300 patients. It's about six months from being closed. You've heard a lot about the adjuvant therapy of kidney cancer. We'll hopefully have those results this year and in the future and we'll understand whether or not treatment in patients that have undergone surgery can benefit from some of the agents that we've developed in the last decade. We are vigorously pursuing autologous personalized vaccine therapy. I happen to be the international principal investigator for this 160 institution trial. It's a trial that if positive can revisit the role that our immune system has in taking a person's own tumor to generate that immune response that we had talked about. This is a trial that's looking at the checkpoint inhibitors when compared with standard treatment. Those are phase three trials and this is a trial that when complete may offer checkpoint inhibitors for patients with previously untreated metastatic disease. This our trial is sponsored by Bristol Meyer Squibb, but there's a series of trials similarly from other companies around the country. In the second, third, and fourth line we have agents that are targeting specific new novel targets, nanoparticles that deliver drugs as you heard from Dr. Posadas in concentrations that are very, very concentrated in very small packages that hopefully get to the cancer without getting to normal tissue and then a first in human study that we're just beginning based upon science that has taken the better part of 15 years to get to the clinic. And ours is just, our program is really just representative of the kinds of kidney cancer programs around the world where people are focusing their energy and time on this disease to help you. And I just reinforced to you that I hope today was helpful, informative. You have many of the emails of the people that presented. You can ask and answer, we can ask and answer questions and hope to see you in the future. Thanks so much for taking your time out and coming today.